Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Aims To Duplicate Januvia Launch Success In 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Launches for Janumet, Arcoxia and Emend IV are keys to continuing the momentum of firm’s turnaround plan, CEO Clark says.

You may also be interested in...



Merck Gains Positive Opinion For Januvia In EU

Firm expects final EU clearance in early April.

Merck Gains Positive Opinion For Januvia In EU

Firm expects final EU clearance in early April.

Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review

FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel